Correlation Between Grupo Aval and Akari Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Grupo Aval and Akari Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Grupo Aval and Akari Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Grupo Aval and Akari Therapeutics PLC, you can compare the effects of market volatilities on Grupo Aval and Akari Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Grupo Aval with a short position of Akari Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Grupo Aval and Akari Therapeutics.

Diversification Opportunities for Grupo Aval and Akari Therapeutics

-0.49
  Correlation Coefficient

Very good diversification

The 3 months correlation between Grupo and Akari is -0.49. Overlapping area represents the amount of risk that can be diversified away by holding Grupo Aval and Akari Therapeutics PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Akari Therapeutics PLC and Grupo Aval is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Grupo Aval are associated (or correlated) with Akari Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Akari Therapeutics PLC has no effect on the direction of Grupo Aval i.e., Grupo Aval and Akari Therapeutics go up and down completely randomly.

Pair Corralation between Grupo Aval and Akari Therapeutics

Given the investment horizon of 90 days Grupo Aval is expected to generate 0.32 times more return on investment than Akari Therapeutics. However, Grupo Aval is 3.16 times less risky than Akari Therapeutics. It trades about 0.0 of its potential returns per unit of risk. Akari Therapeutics PLC is currently generating about -0.01 per unit of risk. If you would invest  219.00  in Grupo Aval on August 31, 2024 and sell it today you would lose (8.00) from holding Grupo Aval or give up 3.65% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy99.73%
ValuesDaily Returns

Grupo Aval  vs.  Akari Therapeutics PLC

 Performance 
       Timeline  
Grupo Aval 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Grupo Aval are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite quite persistent basic indicators, Grupo Aval is not utilizing all of its potentials. The recent stock price mess, may contribute to short-term losses for the institutional investors.
Akari Therapeutics PLC 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Akari Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Grupo Aval and Akari Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Grupo Aval and Akari Therapeutics

The main advantage of trading using opposite Grupo Aval and Akari Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Grupo Aval position performs unexpectedly, Akari Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akari Therapeutics will offset losses from the drop in Akari Therapeutics' long position.
The idea behind Grupo Aval and Akari Therapeutics PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Complementary Tools

My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios